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Fusion is followed by uncoating of the viral core, and
deposition of the following core components into the host
cell cytoplasm: viral RNA genome, reverse transcriptase
(RT), integrase (IN), and virion regulatory proteins. RT
begins assembling DNA copies (cDNA) of the HIV genome
at a rate proportional to the activation state of the host
cell. Since this is a reversal of the usual biological process
- in which DNA is the template for RNA - it is described
as reverse transcription. In activated cells, complete
synthesis of cDNA occurs within 3 hours; in quiescent cells
the process takes somewhat longer. cDNA enters the host
cell nucleus as a large molecular complex comprising cDNA,
RT and IN. Translocation depends upon specialised
transportation molecules that are associated with pores in
the nuclear membrane. The rate of nuclear translocation is
also influenced by the activation state of the cell. Once
inside the nucleus cDNA inserts into the host cell DNA at
sites that are specially prepared by the action of IN.
Integrated cDNA is termed 'proviral DNA' and contains the
blueprint for creating virus progeny. As the host cell moves
through its growth cycle, proviral DNA is transcribed into
messenger RNA which is exported into the cytoplasm.
There mRNA is translated into new viral structural
components, enzymes and genomic elements. Protease
(PR) is an essential viral enzyme that is synthesised during
this process.
Under the influence of PR, viral components associate with
host cell membrane and then bud off as immature virions.
PR activity continues after detachment from the host cell;
the molecular changes that occur under the influence of
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Dominant co-receptor use· Major gp120 Cytopathic Transmissibility
component characteristict
CCR5 V3 loop Non-syncitium- High'
inducing
CXCR4 V3loop Syncitium-inducing Low"
• At I~a.st fivt other ro-re<:eptors havf been idfntififd; th6r rolf has not bet"n fully flucidaterl.
t Syncitium-inducing virus gfnffally rfPlicatfS faStfr and is believed to bf mar!' pathogfnic.
+langffhans c~ls predominantly expre'iS CCR5 in vivo, explaining in part thf preferfntial transmission of NSI virus.
TABLE I. MAJOR CELLULAR TARGETS FOR HIV IN VIVO
HUMAN IMMUNODEFICIENCY VIRUS
HIV LIFE CYCLE AND POTENTIAl TARGETS
FOR DRUG ACTIVITY
The major receptor that facilitates binding of HIV to human
cells is the CD4 differentiation molecule. Table I shows the
main cell types that bear CD4 or CD4-like molecules and
are infected by HIV in vivo. Following HIV infection there is
progressive depletion and/or dysfunction of CD4+ T
Iymphocytes that results in immunodeficiency. A viral
surface glycoprotein known as gp120 binds to the CD4
molecule. On binding, a conformational change occurs in
the gp120-CD4 complex that allows gp120 to interact with
one or more cellular co-receptors. The gp120-co-receptor
interaction triggers a further conformational change in
gp41, another of the viral surface structures; hydrophobic
portions of this molecule merge with the target cell
membrane, inducing fusion between virus and cell.
The mix of cell surface receptors and co-receptors, together
with the structure of the gp120 molecule, largely
determine HIV tropism for different cell types, cytolytic
activity and transmissibility (Table 11).
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TABLE Ill. STAGES IN THE HIV UFE CYCLE THAT ARE TARGETS FOR CURRENTLY AVAIlABLE ANTIRETROVIRAlS





















targeis for pharmacological intervention [Fig. 1). Those
that are exploited by currently available antiretroviral






Maturation: The protein chains in the new viral
particle are cut by the protease enzyme into individual




strands of viral RNA
are converted into
double--stranded DNA "' ~
by the reverse
transcriptase enzyme
Entry inhibitors act at steps 2 and 3
Reverse transcriptase inhibitors act at step 4
Integrase inhibitors act at step 5












infected cell divides, the viral
DNA is "read" making long
chains of proteins, e.g.
gag-pal polypeptide
Ufe cycle target
Fusion between virus and host eel! membranes
Reverse transcription
Virus assembly and maturation
Viral budding
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The life-cycle of HIV presents a wide varieiy of potential
this enzyme ensure maturation into a fully infectious
virion.
